Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.
Alex J LiuBenjamin E UeberrothPatrick W McGarrahSkye A Buckner PettyAyse Tuba KendiJason StarrTimothy J HobdayThorvardur R HalfdanarsonMohamad Bassam SonbolPublished in: The oncologist (2021)
High-grade well-differentiated neuroendocrine tumors (NET G3) are considered a different entity from low-grade NET and neuroendocrine carcinoma in terms of prognosis and management. The oral combination of capecitabine and temozolomide is considered a good option in the management of metastatic NET G3 and may be preferred. FOLFOX is another systemic option with reasonable efficacy. Similar to other well-differentiated neuroendocrine tumors, peptide receptor radionuclide therapy seems to have some efficacy in these tumors.